Carving a new trail in immunology
First Tracks Biotherapeutics is a clinical‑stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases.
Where bold science becomes action
Theresa working in the First Tracks lab
First Tracks Bio is built on a simple but powerful belief: scientific exploration and innovation matter most when they create impact.
Our name reflects the pioneering spirit that drives us. We embrace the courage to go first, the confidence to carve a new trail and the excitement of transforming scientific insight into meaningful impact for all our stakeholders.
Guided by this spirit, we pursue a focused strategy to efficiently advance a high value immunology portfolio that delivers meaningful impact where it’s needed most.
Because patients deserve a future that looks nothing like their past. A future where autoimmune diseases no longer define a life, a family or a dream.
News Releases
First Tracks News
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share.
First Tracks News
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced positive top-line results from Cohort 1 (gluten challenge) of ANB033’s Phase 1b trial in celiac disease (CeD). ANB033, an investigational, subcutaneously administered CD122 antagonist, is designed to inhibit the signaling of both IL-15 and IL-2 on immune cells.
First Tracks Events
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.